8 April 2022
("Physiomics") or ("the Company")
Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a contract by new client, the Servier Group ("Servier"), an international pharmaceutical company headquartered in France. Cancer is one of Servier's priority therapy areas and it has a particular focus on immunotherapies and monoclonal antibodies for difficult to treat diseases with high unmet medical needs.
Physiomics will be providing specialist mathematical modelling services using its Virtual Tumour software platform to model and simulate the effect of a number of immuno-oncology combinations involving Servier drugs in development in pre-clinical and clinical settings. It is anticipated that the project will be completed over the course of the next 7-8 months.
Physiomics CEO, Dr Jim Millen, commented: "We are delighted to have been selected by Servier, one of France's leading pharmaceutical companies with a truly global outlook as its partner for this modelling and simulation project focused on pre-clinical and translational modelling of a novel immuno-oncology agent in development. We look forward to working with its talented scientists."
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.